Literature DB >> 32193631

Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation.

Annalen Bleckmann1,2, Sascha Dierks3, Hans-Ulrich Schildhaus4, Niels Hellige5, Ulrike Bacher3,6, Lorenz Trümper3, Gerald Wulf3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32193631      PMCID： PMC7782442          DOI： 10.1007/s00277-020-03974-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  14 in total

1.  PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

Authors:  Sarah A Meadows; Francisco Vega; Adam Kashishian; Dave Johnson; Volker Diehl; Langdon L Miller; Anas Younes; Brian J Lannutti
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

2.  The genetic landscape of mutations in Burkitt lymphoma.

Authors:  Cassandra Love; Zhen Sun; Dereje Jima; Guojie Li; Jenny Zhang; Rodney Miles; Kristy L Richards; Cherie H Dunphy; William W L Choi; Gopesh Srivastava; Patricia L Lugar; David A Rizzieri; Anand S Lagoo; Leon Bernal-Mizrachi; Karen P Mann; Christopher R Flowers; Kikkeri N Naresh; Andrew M Evens; Amy Chadburn; Leo I Gordon; Magdalena B Czader; Javed I Gill; Eric D Hsi; Adrienne Greenough; Andrea B Moffitt; Matthew McKinney; Anjishnu Banerjee; Vladimir Grubor; Shawn Levy; David B Dunson; Sandeep S Dave
Journal:  Nat Genet       Date:  2012-11-11       Impact factor: 38.330

Review 3.  Update on Burkitt Lymphoma.

Authors:  Kieron Dunleavy; Richard F Little; Wyndham H Wilson
Journal:  Hematol Oncol Clin North Am       Date:  2016-12       Impact factor: 3.722

Review 4.  Burkitt's lymphoma.

Authors:  Elizabeth M Molyneux; Rosemary Rochford; Beverly Griffin; Robert Newton; Graham Jackson; Geetha Menon; Christine J Harrison; Trijn Israels; Simon Bailey
Journal:  Lancet       Date:  2012-02-13       Impact factor: 79.321

Review 5.  Oncogenic mechanisms in Burkitt lymphoma.

Authors:  Roland Schmitz; Michele Ceribelli; Stefania Pittaluga; George Wright; Louis M Staudt
Journal:  Cold Spring Harb Perspect Med       Date:  2014-02-01       Impact factor: 6.915

Review 6.  Idelalisib for the treatment of non-Hodgkin lymphoma.

Authors:  Solomon A Graf; Ajay K Gopal
Journal:  Expert Opin Pharmacother       Date:  2016-01-28       Impact factor: 3.889

Review 7.  Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.

Authors:  Andrew Davies
Journal:  Expert Rev Hematol       Date:  2015-10       Impact factor: 2.929

8.  The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.

Authors:  G Wan; C Pehlke; R Pepermans; J L Cannon; D Lidke; A Rajput
Journal:  Cell Death Discov       Date:  2015-10-19

9.  PIK3CA mutations in advanced cancers: characteristics and outcomes.

Authors:  Filip Janku; Jennifer J Wheler; Aung Naing; Vanda M Stepanek; Gerald S Falchook; Siqing Fu; Ignacio Garrido-Laguna; Apostolia M Tsimberidou; Sarina A Piha-Paul; Stacy L Moulder; Jack J Lee; Rajyalakshmi Luthra; David S Hong; Razelle Kurzrock
Journal:  Oncotarget       Date:  2012-12

Review 10.  Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.

Authors:  Lindsay C Spender; Gareth J Inman
Journal:  Cancer Manag Res       Date:  2014-01-09       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.